Naratriptan
Post Traumatic Headache
Cady, Roger, M.D.Small moleculePhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Post Traumatic Headache cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eptinezumab Sunnybrook Health Sciences Centre | Phase 3 | B |
Same molecule, other indications
Naratriptan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →